Prothena Corporation plc Ordinary Shares
PRTAProthena Corporation plc is a biotechnology company focused on developing therapies for neurodegenerative and rare diseases. Founded in 2012 and headquartered in Dublin, Ireland, it leverages its expertise in immunology and protein biology to create innovative treatments, primarily targeting conditions such as Alzheimer's disease, Parkinson's disease, and other amyloid-related disorders. The company's approach often involves antibody discovery, molecular engineering, and collaboration with partners to advance its drug pipeline.
Company News
Novo Nordisk presented Phase 2 trial results for Coramitug, an antibody targeting transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The drug showed a statistically significant reduction in heart failure biomarker NT-proBNP and was well-tolerated.
The FDA now requires an additional MRI scan before the third Leqembi infusion to detect early signs of brain swelling (ARIA-E), a rare but potentially fatal side effect of the Alzheimer's treatment.
Kuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Prothena Corporation PLC. Shareholders may be entitled to damages and corporate governance reforms.
The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical tr...
Prothena's Parkinson's drug prasinezumab, partnered with Roche, missed the primary endpoint in a Phase 2b study, but showed potential clinical benefits in secondary analyses.
